Go to deals
Healthcare | Private Equity

BaltCap has sold InMedica to INVL Baltic Sea Growth Fund

BaltCap and a founder of InMedica have sold the company to INVL Baltic Sea Growth Fund. Financial details have not been disclosed.

InMedica is one of the largest private network of healthcare clinics in Lithuania. Employing more than 350 specialists, InMedica provides a vast range of medical services.

INVL Baltic Sea Growth Fund is a closed-end investment fund intended for professional investors and is focused on growth capital, buy-out, and buy-and-build investments, and will seek to form a diversified portfolio. INVL Baltic Sea Growth Capital Fund began its operation sin October 2018.

BaltCap is the leading independent private equity firm focusing on small and mid-market buyout and expansion capital investments in the Baltic States. Since 1995, BaltCap has managed several private equity and venture capital funds with a total capital of over US$295 million and has made more than 60 investments.

Oaklins' team in Lithuania advised the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Martynas  Visockas

Martynas Visockas

Partner

Vilnius, Lithuania
Oaklins Baltics
 Marius  Binkevičius

Marius Binkevičius

Partner

Vilnius, Lithuania
Oaklins Baltics

Related deals

Groupe Nature acquires Winco
Consumer & Retail | Healthcare

Groupe Nature acquires Winco

Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.

Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

Learn more
Shield Therapeutics has raised funds
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Learn more